COST-CONSEQUENCE ANALYSIS OF SUBCUTANEOUS ABATACEPT VERSUS ADALIMUMAB IN SEROPOSITIVE, EROSIVE EARLY RHEUMATOID ARTHRITIS - BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

被引：0
|
作者：
Marinheiro, P. [1 ]
Faustino, P. [1 ]
Watanabe, S. [2 ]
Lima, P. [2 ]
机构：
[1] Bristol Myers Squibb, New York, NY USA
[2] IQVIA, Sao Paulo, Brazil
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2020年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
111
引用
收藏
页码：136 / 136
页数：1
相关论文
共 50 条
  • [1] COST-CONSEQUENCE ANALYSIS OF SUBCUTANEOUS ABATACEPT VERSUS ADALIMUMAB IN RHEUMATOID ARTHRITIS BY ACPA STATUS - BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Marinheiro, P.
    Faustino, P.
    Watanabe, S.
    Lima, P.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 136 - 136
  • [2] COST-PER-RESPONSE ANALYSIS OF SUBCUTANEOUS ABATACEPT VERSUS ADALIMUMAB FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS - BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Alves, Nathalie
    Marinheiro, Paola
    Bemardino, Graziela
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S41 - S41
  • [3] Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada
    Jason Foo
    Chaienna Morel
    Martin Bergman
    Christoph Baerwald
    José Manuel Rodriguez-Heredia
    Alexander Marshall
    Carlos Polanco-Sánchez
    Roelien Postema
    Rheumatology International, 2019, 39 : 1621 - 1630
  • [4] Cost per Response for Abatacept Versus Adalimumab in Patients with Seropositive, Erosive, Early Rheumatoid Arthritis in the US, Germany, Spain and Canada
    Foo, J.
    Heredia, J. M. Rodriguez
    Sanchez, C. Polanco
    Mtibaa, M.
    Herrmann, K. H.
    Alemao, E.
    Postema, R.
    Baerwald, C.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [5] Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada
    Foo, Jason
    Morel, Chaienna
    Bergman, Martin
    Baerwald, Christoph
    Manuel Rodriguez-Heredia, Jose
    Marshall, Alexander
    Polanco-Sanchez, Carlos
    Postema, Roelien
    RHEUMATOLOGY INTERNATIONAL, 2019, 39 (09) : 1621 - 1630
  • [6] COST PER RESPONSE FOR ABATACEPT VERSUS ADALIMUMAB IN PATIENTS WITH SEROPOSITIVE EROSIVE, EARLY RHEUMATOID ARTHRITIS IN THE UNITED STATES, GERMANY, SPAIN AND CANADA
    Foo, Jason
    Rodriguez-Heredia, Jose M. R.
    Polance Sanchez, Carlos
    Mtibaa, Mondher
    Herrmann, Kirsten H.
    Alernaoe, Eve
    Postema, Roelien
    Baerwald, Christoph
    RHEUMATOLOGY, 2018, 57
  • [7] COST ANALYSIS OF RITUXIMAB VERSUS INFLIXIMAB, ADALIMUMAB, ETANERCEPT AND ABATACEPT FOR RHEUMATOID ARTHRITIS FROM THE PERSPECTIVE OF A PRIVATE PAY IN BRAZIL
    Santos, E. A.
    Saggia, M. G.
    VALUE IN HEALTH, 2009, 12 (07) : A522 - A522
  • [8] COMPARISON OF COST- EFFICACY OF SUBCUTANEOUS ABATACEPT VERSUS ADALIMUMAB IN THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS
    Khanna, D.
    Massarotti, E.
    Rosenblatt, L.
    Budd, D.
    Sabater, J.
    Hebden, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 340 - 341
  • [9] A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis
    Jimenez-Morales, Alberto
    Caliz, Rafael
    Aceituno, Susana
    Prades, Miriam
    Blanch, Carles
    REUMATOLOGIA CLINICA, 2021, 17 (09): : 536 - 542
  • [10] Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study
    Areej S. Albahdal
    Amjad M. Alotaibi
    Miteb A. Alanazi
    Norah Abanmy
    Monira Alwhaibi
    Yazed AlRuthia
    Cost Effectiveness and Resource Allocation, 22
12345